Lung Cancer Trial, By Invitation NCT07390565 Sponsor: LI FENG Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, By Invitation

NCT07390565
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with extensive-stage small cell lung cancer according to both Western medical standards and traditional Chinese medicine criteria (specifically a pattern described as kidney deficiency with qi deficiency and blood stasis)
  • People who have been newly diagnosed with extensive-stage small cell lung cancer and have not yet received any Western medical cancer treatments, and who have measurable areas of disease that can be tracked
  • People who are planned to receive at least 2 cycles of a first-line treatment combining immunotherapy, a platinum-based chemotherapy, and a drug called etoposide
  • People who do not have, and have not previously had, any other type of primary cancer
  • People aged 18 or older who are expected to live for at least 3 months
  • People whose general physical functioning is rated at 60 points or above on a standard scale called the Karnofsky Performance Status (confirm with trial site for exact scoring details)
  • People whose thinking and understanding are clear enough to complete study questionnaires
  • People who have agreed to take part in the study treatment and have signed a consent form

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who are pregnant or breastfeeding, or who have serious conditions affecting the heart, lungs, liver, kidneys, or blood
  • People who are currently participating in another clinical trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 10 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
LI FENG
Registry
ClinicalTrials.gov
Start date
17 February 2026
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Disease Control Rate(DCR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 10 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov